ArticlemBio2019
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 52 citations in OpenAlex.
- Abolishing PorB-induced mitophagy enhances gonococcal outer membrane vesicle vaccine efficacy.Emerging microbes & infections · 2026Article
- Preclinical characterization of immune responses induced by a candidate gonococcal native outer membrane vesicle vaccine.mSphere · 2026Article
- Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.NPJ vaccines · 2026Article
- MtrE Loop2-specific multiple antigenic peptide vaccine and monoclonal antibody confer complement-dependent protection against Neisseria gonorrhoeae.NPJ vaccines · 2026Article
- Review
- Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection.The Journal of infectious diseases · 2025Article
- Structure-based engineering of a nutrient acquisition protein enhances neutralizing antibodies and protection for the development of a gonococcal vaccine.bioRxiv : the preprint server for biology · 2025Article
- Contribution of the different Neisseria gonorrhoeae lipooligosaccharide structural variants to functional responses elicited by GMMA outer membrane vesicles.NPJ vaccines · 2025Article
- The gonococcal vaccine candidate antigen NGO1701 is a N. gonorrhoeae periplasmic copper storage protein.PLoS pathogens · 2025Article
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.NPJ vaccines · 2025Article
- Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosa.Frontiers in immunology · 2025Article
- PreclinicalFrontiers in immunology · 2025Article
- Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context.The Journal of infectious diseases · 2024Review
- Vaccine value profile for Neisseria gonorrhoeae.Vaccine · 2024Article
- Article
- Addressing Sexually Transmitted Infections Due toMicroorganisms · 2024Review
- Review
- Characterization of protective immune responses againstHeliyon · 2024Article
- Experimental Urethral Infection with Neisseria gonorrhoeae.Current topics in microbiology and immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Sunita GulatiDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Michael W PenningtonAmbioPharm, Inc., North Augusta, South Carolina, USA.
Andrzej CzerwinskiPeptides International Inc., Louisville, Kentucky, USA.
Darrick CarterInfectious Diseases Research Institute, Seattle, Washington, USA.
Bo ZhengDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Nancy A NowakDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Rosane B DeOliveiraDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jutamas ShaughnessyDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
George W ReedDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Sanjay RamDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Peter A RiceDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA peter.rice@umassmed.edu.
University of Massachusetts Chan Medical School · USInfectious Disease Research Institute · USPeptides International (United States) · US
Funding
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoeaR01AI132296 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2017 to 2021
$5.5MA novel vaccine against multidrug-resistant gonorrheaR01AI141181 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2019 to 2023
$4.3MImmune defenses against Neisseria gonorrhoeaeR01AI114790 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2015 to 2019
$3.1MVaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia coU01AI118161 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2014 to 2017
$2.0MLipooligosaccharide mimitope vaccines against Neisseria gonorrhoeaeR01AI114710 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RICE, PETER A. · 2015 to 2018
$1.8MNIAID NIH HHS R01 AI114710NIAID NIH HHS R01 AI114790NIAID NIH HHS R01 AI132296NIAID NIH HHS R01 AI141181NIAID NIH HHS U01 AI118161
Abstract
The global spread of multidrug-resistant strains of
Indexed as
AnimalsAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial VaccinesEpitopesFemaleGonorrheaImmunoglobulin GLipopolysaccharidesMiceMice, Inbred BALB CNeisseria gonorrhoeaePeptidesAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial VaccinesEpitopesImmunoglobulin Glipid-linked oligosaccharidesLipopolysaccharidesPeptidesantibody functionexperimental infectionimmunization/vaccineNeisseria gonorrhoeaepeptidevaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.